An observational study in Drug Addiction, HIV/AIDS and Hepatitis C, Chronic, sponsored by French National Agency for Research on AIDS and Viral Hepatitis. Status unknown at 1 site in Senegal. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-08.
Sponsored by French National Agency for Research on AIDS and Viral Hepatitis · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main purpose of the CoDISEN cohort study is to propose a model of prevention and care for HIV and viral hepatitis adapted to the needs of people who inject drugs (PWID) in Dakar, Senegal.
THE UNODC estimated the number of consumers of injectable drugs at 1,02 millions in 2012 in Africa among which 12,1 % lived with HIV. Prevalences of HIV, chronic hepatitis C and B among people who inject drugs remain little documented in Sub-Saharan Africa. The transmission of HCV in Africa is mainly hospital-borne, bound to a precarious transfusional and therapeutic safety. However, the transmission by intravenous drug use emerges as a new stake in public health in urban areas. The report of a strong HIV prevalence in the population of PWID in the sub-region ( for example, In 2007, in the Cape Verde, prevalence of the HIV was 14 % in emprisoned PWID against 0,8 % in the general population) contributed to assert the reality of the use of intravenous drugs in the region and the vulnerability of this population. Senegal, a country with an concentrated HIV epidemic [0,5 % prevalence in 2012, WHO source] is the first country of western Africa to have measured prevalence of HIV (5,2 %), HBV (7,9 %) and HCV (23,3 %) in PWID (Study ANRS 12243). In view of these results, the Senegalese authorities introduced from October, 2011 in Dakar, activities of harm reduction by means of a mobile team of social workers and mediators allowing individual and collective activities of prevention, needle exchange program, references for care and follow-up, as well as a opioid substitution program in a methadone center (CEPIAD) located in Dakar, first of its kind in Western Africa. The objective of the present research project thus is to estimate the impact of a strategy of " test and treat " of HIV and harm reduction initiatives on the prevalence and incidence of HIV, HBV and HCV infections in an population of injectable drug consumers followed in the methadone center ( CEPIAD) of Dakar, Senegal
2,241 studies on the registry are indexed under Substance-Related Disorders; 409 are open to participants now.
This study's enrollment of 208 is below the median of 251 across 299 observational studies indexed under Substance-Related Disorders.
Browse Substance-Related Disorders studies →French National Agency for Research on AIDS and Viral Hepatitis is the lead sponsor of 86 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Population of active injecting drug users who are seeking care at the CEPIAD, Dakar, Senegal.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
incidence of HIV
number of participants infected with HIV at inclusion and acquiring HIV during follow-up
Time frame: 24 months
incidence of hepatitis C infection (HCV)
number of participants infected with HCV at inclusion and acquiring HCV during follow-up
Time frame: 24 months
incidence of hepatitis B infection (HBV)
number of participants infected with HBV at inclusion and acquiring HBV during follow-up
Time frame: 24 months
incidence of relevant coinfections and comorbidities
number of patients developping sexually transmitted infections, tuberculosis and other conditions -% Test realized / test planned
Time frame: 24 months
Retention rate and its determinants
Number of participants retained in the cohort follow-up + analysis of determinants of retention
Time frame: 24 months
mortality rate and determinants
Number of participants dead during follow-up + analysis of determinants of death * evolution of CD4 and HIV viral load in participants with HIV and treated with ARVs, HBV viral load , and HCV viral load in participants with viral hepatitis B and C * Incidence of clinical events and biological of interest
Time frame: 24 months
Access to treatment of HCV, HBV infections and other coditions requiring specific therapeutical management
Number of patients treated for HIV, HBV, HCV and other medical conditions according to national or international guidelines recommendations
Time frame: 24 months
Effectiveness of tuberculosis regimens
Number of cured patients / number of patients initiating treatment
Time frame: 24 months
Plan to share: Yes — IPD that can be shared include study protocol, statistical analysis plan, inform consent form and anonymized database
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Duration of the study and 2 years after study closure
Access criteria: Any sharing of information related to the study must be approved by the Scientific committee and the sponsor.
No publications or documents are linked to this record.
Started Aug 2016 (actual). Primary completion is estimated for Jun 2021, 58 months after the start.
Of 123 non-industry observational studies under Substance-Related Disorders, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 60. This study's planned 58 months is above that.
Counting every sponsor, half of 134 studies reached it within 36 months; a quarter within 18 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
French National Agency for Research on AIDS and Viral Hepatitis